RxDoctor Payments Data

Laura Hammitt

Denver, CONPI 1659427276

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $6,380 of the $7,064 with a category attached, or 90.3%. Every reported general payment came from a single manufacturer, Merck.

$7,064in general payments, 2019–2025

Across 7 payments — averaging $1009.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$7K
$4,843,587in research payments, 2019–2025

Across 203 payments — averaging $23,860 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$3.5M
  • Pfizer$1M
  • AstraZeneca$299K
  • Sanofi Pasteur Inc.$27K

What the payments were for

  • Consulting fees$6,38090%
  • Travel & lodging$4346%
  • Food & beverage$2494%

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck7$7,064

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →